Immunotherapy and the evolving trajectory of type 1 diabetes: management to prevention
Journal of Prescribing Practice · 02.07.2026 · 8 (7) · 274-276
DOI: 10.12968/jprp.2026.0075 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Prescribing Practice, erschienen am 02.07.2026. Verfasst von Aysha Mendes. Die Arbeit nennt 7 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aysha Mendes explores the evidence behind teplizumab, reviews the wider immunotherapy landscape in T1D and considers the implications of this evolving field for prescribing practice
Zitieren
APA
Mendes, A. (2026). Immunotherapy and the evolving trajectory of type 1 diabetes: management to prevention. Journal of Prescribing Practice, 8(7), 274-276. https://doi.org/10.12968/jprp.2026.0075
Vancouver
Mendes A. Immunotherapy and the evolving trajectory of type 1 diabetes: management to prevention. Journal of Prescribing Practice. 2026;8(7):274-276. doi:10.12968/jprp.2026.0075
BibTeX
@article{Mendes2026,
author = {Mendes, Aysha},
title = {Immunotherapy and the evolving trajectory of type 1 diabetes: management to prevention},
journal = {Journal of Prescribing Practice},
year = {2026},
volume = {8},
number = {7},
pages = {274--276},
doi = {10.12968/jprp.2026.0075}
}
EUVIMED